Protein expression of cell cycle regulator, p27(Kip1), correlates with histopathological grade of non-Hodgkin's lymphoma

Japanese Journal of Cancer Research

Volumn 90, Issue 11, 1999, Pages 1262-1269

  Kudoh, Shiori ^a   Kumaravel, Tirukalikundram S ^a   Kuramavel, Bharathy ^a   Eguchi, Minenori ^a   Asaoku, Hideki ^b   Dohy, Hiroo ^b   Fujiwara, Megumi ^b   Sasaki, Naomi ^c   Tanaka, Kimio ^a   Kamada, Nanao ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Hiroshima Red Cross Atom Bomb S ^*  (Japan)

^c Kure Kyousai Hospital   (Japan)

Author keywords

Non Hodgkin's lymphoma; p27(Kip1)

Indexed keywords

CYCLIN D1; CYCLIN E; PROTEIN P27;

ARTICLE; B CELL LYMPHOMA; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 0032805133     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00706.x     Document Type: Article

References (50)

1. Withers, D. A., Harvey, R. C., Faust, J. B., Melnyk, O., Carey, K. and Meeker, T. C. Characterization of a candidate bcl-1 gene. Mol. Cell. Biol., 11, 4846-4853 (1991).
2. Seto, M., Yamamoto, K., Iida, S., Akao, Y., Utsumi, K. R., Kubonishi, I., Miyoshi, I., Ohtsuki, T., Yawata, Y., Namba, M., Motokura, T., Arnold, A., Takahashi, T. and Ueda, R. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene, 7, 1401 (1992).
3. Motokura, T. and Arnold, A. PRAD1/cyclin D1 protooncogene: genomic organization, 5′ DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chromosom. Cancer, 7, 89-95 (1993).
4. Lamine, G. A., Fantl, V., Smith, R., Schuuring, E., Brookes, S., Michael-ides, R., Dickson, C., Arnold, A. and Peters, G. D11s128, a putative oncogene on chromosome 11q13 is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1, Oncogene, 6, 439-444 (1991).
5. Jiang, W., Zhang, Y. J., Kahnm, S. M., Hollstein, M. C., Santell, R. M., Lu, S. H., Harris, C. C., Montesano, R. and Weinstein, I. B. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. USA, 90, 9026 (1993).
6. Buckley, M. F., Sweeney, K. J., Hamilton, J. A., Sini, R. I., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K., Musgrove, E. A. and Sutherland, R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8, 2127 (1993).
7. Kramer, M. H., Hermans, J., Wijburg, E., Philippo, K., Geelen, E., Kriken, van J. H., Jong, de D., Maartense, E., Schuuring, E. and Kluin, P. M. Clinical relevance of bcl-2, bcl-6, and myc rearrangements in diffuse large B-cell lymphoma. Blood, 92, 3152-3162 (1998).
8. Ladanyi, M. The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma. Cancer Surv., 30, 59-75 (1997).
9. Kuefer, M. U., Look, A. T., Pulford, K., Behm, F. G., Pattengale, P. K., Mason, D. Y. and Morris, S. W. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood, 90, 2901-2910 (1997).
10. Imamura, J., Miyoshi, I. and Koeffler, H. P. p53 in hematologic malignancies. Blood, 84, 2412-2421 (1994).
11. Dupin, N., Fisher, C., Kellam, P., Ariad, S., Tulliez, M., Franck, N., van Marck, E., Salmon, D., Gorin, I., Escande, J. P., Weiss, R. A., Alitalo, K. and Boshoff, C. Distribution of human herpes virus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease and primary effusion lymphoma. Proc. Natl. Acad. Sci. USA, 96, 4546-4551 (1999).
12. Sherr, C. J. Cancer cell cycles. Science, 274, 1672-1677 (1996).
13. Hunter, T. and Pines, J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell, 79, 573-582 (1994).
14. Hunter, T. and Pines, J. Cyclins and cancer. Cell, 66, 1071-1074 (1991).
15. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816 (1993).
16. Kip1, a cyclincdk inhibitor, links transforming growth factor-ß and contact inhibition to cell cycle arrest. Genes Dev., 8, 9-22 (1994).
17. kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78, 59-66 (1994).
18. Toyoshima, H. and Hunter, T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78, 67-74 (1994).
19. Nobor, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K. and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancer. Nature, 368, 753-756 (1994).
20. Serrano, M., Hannon, G. J. and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366, 704-707 (1993).
21. Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G. and Xiong, Y. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev., 15, 2939-2952 (1994).
22. Lukas, J., Muller, H., Bartkova, J., Spitkovsky, D., Kjerulff, A. A., Jansen-Durr, P., Strauss, M. and Bartek, J. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J. Cell Biol., 125, 625 (1994).
23. Baldin, V., Lukas, J., Marcote, M. J., Pagano, M. and Draetta, G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev., 7, 323 (1993).
24. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825 (1993).
25. Sato, Y., Suto, Y., Pietenpol, J., Golub, T. R., Gilliland, D. G., Davis, E. M., Le Beau, M. M., Roberts, J. M., Vogelstein, B. and Rowley, J. D. TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. Blood, 86, 1525-1533 (1995).
26. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817 (1993).
27. Toyoshima, H. and Hunter, T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78, 67 (1994).
28. Slingerland, J. M., Hengst, L., Pan, C. H., Alexander, D., Stampfer, M. and Reed, S. I. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol. Cell. Biol., 14, 3683-3694 (1994).
29. Kiyokawa, H., Kineman, Rd., Manova-todorovam, K. O., Soaresm, V. C., Hoffman, K. S., Ono, M., Khanam, D., Hayday, A. C., Frohman, L. A. and Koff, A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 85, 721-732 (1996).
30. Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y. and Nakayama, K. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 85, 707-720 (1996).
31. Fero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Firpo, E., Polyak, K., Tsai, L. H., Broudy, V., Perlmutter, R. M., Kaushansky, K. and Roberts, J. M. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 85, 733-744 (1996).
32. Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn. J. Cancer Res., 88, 625-629 (1997).
33. Ponce-Castaneda, M. V., Lee, M. H., Latres, E., Polyak, K., Lacombe, L., Montgomery, K., Mathew, S., Krauter, K., Sheinfeld, J., Massague, J. and Cordon-Carlo, C. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res., 55, 1211-1214 (1995).
34. Kawamata, N., Seriu, T., Koeffler, H. P. and Bartram, C. R. Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTSI/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas. Cancer, 77, 570-575 (1996).
35. Esposito, V., Baldi, A., De Luca, A., Groger, A. M., Loda, M., Giordano, G. G., Caputi, M., Baldi, F., Pagano, M. and Giordano, A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res., 57, 3381-3385 (1997).
36. Fredersdorf, S., Burns, J., Milne, A. M., Packham, G., Fallis, L., Gillett, C. E., Royds, J. A., Peston, D., Hall, P. A., Hanby, A. M., Barnes, D. M., Shousha, S., O'Hare, M. J. and Lu, X. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA, 94, 6380-6385 (1997).
37. Non-Hodgkin's lymphoma pathologic classification project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a Working Formulation for clinical usage. Cancer, 49, 2112-2135 (1982).
38. Kamada, N., Dohy, H., Okada, K., Oguma, N., Kurumoto, A., Tanuka, K. and Uchino, H. In vivo and in vitro activity of neutrophil alkaline phosphatase in acute myelocytic leukemia with 8;21 translocation. Blood, 58, 1213-1217 (1981).
39. Tan, P., Cady, B., Wanner, M., Worland, P., Cukor, B., Magi-Gulluzzi, C., Lavin, P., Draetta, G., Pagano, M. and Loda, M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a.b) invasive breast carcinomas. Cancer Res., 57, 1259-1263 (1997).
40. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M. and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3, 231-234 (1997).
41. Coats, S., Flanagan, W. M., Nourse, J. and Roberts, J. M. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science, 272, 877 (1996).
42. Sherr, C. J. Cancer cell cycles. Science, 274, 1672 (1996).
43. Toyoshima, H. and Hunter, T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity is related to p21. Cell, 78, 67 (1994).
44. Peter, M. and Herskowitz, I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell, 79, 181 (1994).
45. Erlanson, M., Portin, C., Linderholm, B., Lindh, J., Roos, G. and Landberg, G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas -prognostic implications. Blood, 92, 770-777 (1998).
46. Katayose, Y., Kim, M., Rakkar, A. N., Li, Z., Cowan, K. H. and Seth, P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res., 57, 5441-5445 (1997).
47. Inaba, T., Matsusime, H., Valentine, M., Roussel, M. F., Sherr, C. J. and Look, A. T. Genomic organization, chromosomal localization and independent expression of human cyclin D genes. Genomics, 13, 565-574 (1992).
48. Aguilera, N. S., Bijwaard, K. E., Duncan, B., Krafft, A. E., Chu, W. S., Abbondanzo, S. L., Lichy, J. H. and Taubenberger, J. K. Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas. Am. J. Pathol., 153, 1960-1976 (1998).
49. Keyomarsi, K., Conte, D., Jr., Toyofuku, W. and Fox, M. P. Deregulation of cyclin E in breast cancer. Oncogene, 11, 941-950 (1995).
50. Keyomarsi, K. and Herliczek, T. W. The role of cyclin E in cell proliferation, development and cancer. Prog. Cell Cycle Res., 3, 171-191 (1997).